SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : DYAX: Dyax Corp.
DYAX 38.410.0%Jan 25 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (60)3/15/2003 7:24:39 PM
From: dalroi  Read Replies (1) of 197
 
any idea what will happen to the corvas deal during the merger ?

Corvas
In September 2001, we entered into a collaboration agreement with Corvas International, Inc. to discover and develop cancer therapeutics focused on serine protease inhibitors. In the research phase of the collaboration, we are using our phage display technology to identify small protein, peptide and antibody compounds that bind to two serine protease targets that were isolated and characterized by Corvas. These compounds will be evaluated principally for cancer treatment using in vitro and in vivo models. Each party bears the expense of its efforts during the research phase. The compounds generated in the collaboration may serve as drug candidates that may be jointly developed by us and Corvas with the development costs to be shared equally by the parties. The parties will also share equally any profits realized from the commercialization of any of the compounds.
< Back to Alliances

AstraZeneca
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News